THE BOARD OF TRUSTEES

EXECUTIVE COMMITTEE

Mr. Richard T. Schlosberg III, Chairman
(Retired) Publisher and CEO, Los Angeles Times

Mr. John E. Newman, Jr., Vice Chairman
Principal, Newman Brothers

Mr. James B. Smith, Jr., Secretary
Chairman, Cox Smith Matthews Inc.

Dr. Ronald K. Calgaard, Ph.D.
Chairman, Ray Ellison Grandchildren Trust

Mr. John R. Hurd
Chief Executive Officer, Hurd Enterprises, Ltd.

Mrs. Abigail G. Kampmann
Chief Executive Officer, Principle Auto

Mr. John C. Kerr
Principal, Moorman Kerr Interests

Mr. Lewis J. Moorman III
Investor

Dr. James "Jamo" Rubin
Chief Executive Officer, TAVIHealth

Mrs. Marsha M. Shields
President, McCombs Foundation

TRUSTEES

Mr. Rex Antini
Managing Director, Sage Energy Co.

Mr. Edward H. Austin, Jr.
Principal, Austin Family Investments

Mr. Richard N. Azar II
General Partner, Sezal Energy, L.P.

Mr. Craig Boyan
Chief Operating Officer, H-E-B

Mr. J. Bruce Bugg, Jr.
Chairman and CEO, Argyle Investment Co., LLC

Mr. Robert M. Cavender
President, Cavender Auto Group

Mrs. Phyllis Slick Cowell
President, Slick Enterprises

Mrs. Barbara B. Dreiben
President, Postal Advantage

Mr. Walter Embrey
Chairman, Embrey Partners, Ltd.

Mr. John W. Feik
CEO, Feik Enterprises LLC

Mrs. Emory Alexander Hamilton
Partner, Groves Alexander

Mrs. Ashley Hixon
Division Operating Officer, Methodist Healthcare System

Mr. Richard Kardys
Group Executive Vice President, Frost Bank

Mr. William R. Klesse
Chairman of the Board, Valero Energy Corporation

Mrs. Carolyn H. Labatt
President and CEO, Computer Solutions

Mrs. Jane B. Lammel
Vice President, Briscoe Ranch, Inc.

Mr. Mark Pitman Mays
Principal, Roding M Capital

Mr. Joe C. McKinney
Vice Chairman, Broadway National Bank

Mr. William G. Moll
(Retired) President & GM, KLRN

Mr. Lew Moorman IV
Entrepreneur

Dr. Dacia Napier
Radiologist

Mr. Charles Urschel Slick
Partner, Slick Enterprises

Mr. John B. Zachry
Chairman and CEO, Zachry Holdings, Inc.

TRUSTEES EMERITUS

Mr. Leroy G. Denman, Jr.
Attorney

Mr. Rugeley Ferguson
Investor/Rancher

Mr. Tom C. Frost
Chairman Emeritus, Frost Bank

Mr. James W. Gorman, Jr.
Investor/Rancher

Mr. William E. Greeney
Chairman, NuStar Energy, L.P.

Mr. George C. Hixon
Investor/Rancher

Mr. B. D. Holt
Chairman, Holt Companies

Mrs. Betty Kelso
Investor/Rancher

Mr. Milton B. Lee
(Retired) CEO, CPS Energy

Mr. B. J. McCombs
Chairman, McCombs Enterprises

Mr. Edward E. Whitacre, Jr.
Chairman Emeritus, AT&T

SPECIAL TRUSTEES

Mr. Adam L. Hamilton
President, Southwest Research Institute

Dr. Andrea Giuffrida
(on behalf of Dr. William L. Heinrich)
Vice President for Research and Interim Associate Professor, University of Texas Health Science Center at San Antonio

Dr. Ricardo Romo
President, University of Texas at San Antonio

HONORARY TRUSTEE

Dr. John P. Howe III
President/CEO, Project HOPE

EX-OFFICIO TRUSTEE

Mr. Charley Hollimon
President, Founder's Council

Mr. Robert McClane
President, McClane Partners, LLC

Ms. Melissa Morgan
President, Texas Biomedical Forum
TABLE OF

CONTENTS

4  President’s Letter
6  About Texas Biomed
8  Fighting Ebola Virus
11 Nonhuman Primates and Livesaving Discoveries
13 Future of Genetics Research at Texas Biomed
16 2014 Research Briefs
19  Financials
20  New Grants and Contracts
22  Your Contribution
23  Circles of Giving
27  The Forum
29  Founder’s Council
32  The Argyle
35  Administration, Faculty and Credits

Structural studies of the drug oxamniquine (3D stick representation) and its sulfotransferase target are being used to develop improved therapies against parasitic blood flukes (Schistosoma spp.) that infect over 200 million people worldwide. Research on schistosomiasis is being done in Dr. Tim Anderson’s laboratory, Texas Biomed Department of Genetics, in collaboration with scientists from the UT Health Science Center at San Antonio (UTHSCSA). Image provided by John Hart, UTHSCSA.
In 2014, Texas Biomed made a significant impact toward combatting human disease and improving the future of human health. It is with great regard I think about the people and the passion that comprise this Institution. People are at the heart of our mission... enhancing lives through discovery.

As an independent, not-for-profit, research institution, Texas Biomed uniquely provides a greater understanding of health and makes discoveries that lead to better diagnostics, preventions, therapies and cures for a number of diseases impacting millions of lives.

What does that impact look like? Let's take a look at the numbers.

Ebola virus spreading through West Africa was a defining moment last year. More than 11,000 people have died so far from the outbreak that began in March 2014. According to the World Health Organization, more than 584,000 people died from malaria in 2013. In the United States, more than 1.1 million people are living with HIV. One in three Americans dies of heart disease, and about 50,000 Americans are diagnosed with Parkinson’s disease annually, just to name a few.

We recognize that these are not simply numbers but lives lost and families and communities impacted. And, it is with this in mind that we seek answers to scientific questions that can change our world.

As the world struggles with these diseases, scientists at Texas Biomed are making major progress in the fight. Collaborations with pharmaceutical companies in the advancement of vaccines against Ebola virus have progressed to human trials in 2015. A new method for sequencing the genomes of individual malaria parasites holds the promise of the design of drugs and vaccines against malaria. Scientists at Texas Biomed have identified new possibilities in vaccine development to protect against the spread of HIV. And, the addition of a regenerative medicine program is working toward drug development and therapies against neurodegenerative disorders, like Parkinson’s disease.

These exciting discoveries belong to all of us. We are able to make progress thanks to our many generous supporters and the vision of our Board of Trustees. This vision, to create a world-class institution dedicated to the scientific advancement of human health, began with our Founder, Thomas Baker Slick, Jr. He saw the impact that science could have on mankind, and together, we are making his vision a reality.

Robert W. Gracy, Ph.D., President and CEO
Texas Biomedical Scientific Leadership Team (pictured left to right): Dr. Michael Olivier was named Chair, Department of Genetics, in September 2014; Dr. Jean Patterson, Chair, Department of Virology & Immunology; Dr. Robert W. Gracy was named President and CEO in July 2014; Dr. Robert Lanford was named Southwest National Primate Research Center Director in March 2014.

“...We recognize that these are not simply numbers but lives lost and families and communities impacted. And, it is with this in mind that we seek answers to scientific questions that can change our world.”
TECHNOLOGY. Invention is a way of life at Texas Biomedical Research Institute. As an independent research institution of nearly 75 years, Texas Biomed has the foundation and flexibility to support advances in human health with unique research in genetics, virology and immunology, regenerative medicine, aging and much more. The Texas Biomed team seeks answers to some of the world's most puzzling health questions so that one day we can fully cure or prevent disease.

MOTIVATION. Inspired by the philanthropic vision of our founder, Thomas B. Slick, Jr., in 1941, Texas Biomed is host to many unique resources, not the least of which are our people. Our team of doctoral-level scientists continuously seek new ways to study hundreds of diseases that impact millions of lives, and our team of more than 350 people are motivated by progress.

PASSION. Scientific discoveries require the support of our entire community, and Texas Biomed is thankful to the thousands of philanthropic supporters who advance our science and our scientists. About 70 percent of the Institute's annual budget is funded from highly competitive, peer-reviewed federal research grants and contracts. Philanthropy constitutes the second-largest portion of the Institute’s budget with nearly 20 percent of Texas Biomed’s expenses met by the generous contributions of foundations, corporations, and individuals, as well as income from Texas Biomed's endowment and royalties.

ASSETS. Excellence requires a commitment to developing our talent and resources. The Institute has the nation’s only privately owned biosafety level 4 laboratory. Designed for maximum containment, the BSL-4 lab allows Texas Biomed investigators to safely study deadly pathogens for which there currently are no treatments or vaccines. Texas Biomed is also home to the Southwest National Primate Research Center and the world’s largest baboon research colony, including a unique pedigreed baboon colony that is invaluable for genetic studies on complex diseases. The Institute enjoys a distinguished history in the innovative, humane, and appropriate use of nonhuman primates in biomedical research. In addition, the AT&T Genomics Computing Center is one of the world’s largest computing clusters dedicated exclusively to human disease genetics research.

COMPLEXITY. The complex demands on biomedical research are numerous. From declining national dollars dedicated to scientific research to worldwide outbreaks of new and recognized viruses for which there are still no cures to national disease epidemics such as obesity and diabetes threatening millions of lives, these challenges can seem overwhelming, but at Texas Biomed, we know that together, we can overcome and discover groundbreaking solutions.

TEAMWORK. A foundation built on cooperation and collaboration is necessary to develop the solutions we need. The Institute partners with hundreds of researchers and institutions around the world, pursuing advances in the prevention and treatment of heart disease, diabetes, obesity, osteoporosis, AIDS, hepatitis, malaria, Ebola virus, Parkinson’s disease, Macular Degeneration, parasitic infections and many other diseases. Together, our people and our passion are making a global impact!
The Texas Biomed team seeks answers to some of the world’s most puzzling health questions so that one day we can fully cure or prevent disease.

For more information about Texas Biomedical Research Institute and its efforts to improve human health, contact the Institute at 210-258-9400 or visit the Website at www.TxBiomed.org.
Last year, the Ebola virus disease outbreak overcame West Africa and spilled into the U.S. when an individual who traveled from Liberia was admitted to a Texas hospital with Ebola virus infection. For scientists in Texas Biomed’s Department of Virology and Immunology (V&I), where they have been conducting experiments on Ebola virus for more than ten years, “It was business as usual,” said Department Chair Dr. Jean Patterson.

With its BioSafety Level – 4 (BSL-4) facilities and nonhuman primate colonies, Texas Biomed has long been at the forefront of research on many dangerous viruses. In fact, Texas Biomed scientists had been conducting tests to verify the most promising candidate vaccines since 2007, but as of the outbreak, a viable vaccine candidate had proven elusive.

As is often the case in science, a failure is never truly a failure when it leads to greater understanding of the disease process and ultimately, promises new hope. Though initial tests on one particular vaccine were hopeful, when Texas Biomed scientists attempted to replicate results in other animals that more closely mimicked human disease, they found that the animal models used with the particular virus strains did not completely address the entire story.

“We realized that the animal model wasn’t characterized as well as it should have been,” said Dr. Ricardo Carrion, V&I Associate Scientist & BSL-4 Lab Scientific Manager.

(Pictured from L to R) Dr. Ricardo Carrion, Jr., Dr. Robert Davey, Dr. Luis Giavedoni, Dr. Jean Patterson, Dr. Andrew Hayhurst, Dr. Anthony Griffiths
This information proved invaluable, as it allowed the team to characterize the virus more completely, which in turn helped to determine which factors were most important. In the process, they developed better animal models with viral strains that could relate more closely to the disease process in humans.

According to Carrion, “Had we not had a vaccine failure, we would not be at the advanced stage we are now in developing a vaccine.”

Vaccines take years to develop and even longer to determine safety. Studying lethal pathogens in a large animal requires a significant amount of space. Over the past few years, the BSL-4 lab had been modified to accommodate more animals and more studies. This also meant that staff adjusted to a 24/7 work cycle, with scientists blocking time to conduct experiments at all hours of the day and night.

In the current BSL-4 lab at Texas Biomed, V&I scientists established a higher throughput system to screen vaccine candidates. The other BSL-4 laboratories in the U.S. have specific missions, thus limiting their ability to test vaccines. Texas Biomed, as the only privately-owned BSL-4 lab, can shift its priorities to fill that void. Additionally, the scientific expertise, advanced standard operating procedures, quality systems and virus stocks make Texas Biomed a preferable lab. When the demand came for enhanced vaccine studies in the wake of the 2014 Ebola virus disease outbreak, scientists worldwide turned to the expertise at Texas Biomed.

“We are viewed as the best program for quality research because we incorporate critiques to continually improve the research process,” Patterson said.

Scientists in the V&I Department are part of an Ebola Working Group facilitated via the National Institutes of Health and the Department of Defense. The existence of such a team means that viruses and knowledge are shared amongst testing sites. Thus, concerted efforts to characterize the virus, develop assays and evaluate the vaccine candidates have improved the research overall. When each site gets the same results, the validity of those results is enhanced.

Developing any vaccine requires an understanding of how the host’s immune system responds to the virus and to the potential vaccine. That’s where Dr. Luis Gavedoni, Scientist and Vice Chair of V&I, comes in. In the Immunology Core Laboratory of the Southwest National Primate Research Center, his team has been verifying the candidate vaccines to see if they elicit the expected immune responses. The immune status of the animal must be characterized prior to challenge by the virus, and then followed while the animal is in the BSL-4 lab.
“We can then correlate these data to guide vaccine trials in humans,” said Giavedoni. Aside from his Ebola vaccine efforts, he is also studying potential AIDS vaccines using the simian immunodeficiency virus (SIV) in rhesus macaques.

The physical limits of the BSL-4 lab space prevent further ramping up of vaccine studies. However, the race to identify drug targets for Ebola and other pathogens has meant a near 20-fold increase in workload this past year in the lab of Dr. Robert Davey, V&I Scientist and Ewing Halsell Scholar. Among those small molecules identified this past year was Tetrandrine, from the Chinese herb *Stephania tetrandra*. This compound blocks the “Two Pore Channels” (TPCs) necessary for Ebola virus to traverse the cell. Having identified the cellular function of this compound, early tests in mice showed that it blocked Ebola infection.

Davey’s findings were featured as the cover article in the journal *Science* in early 2015, and he was recognized as a San Antonio Healthcare Hero. The research does not stop here, of course. The next step will be to conduct tests on animal models that mimic human disease. Time is critical in the search for a cure for Ebola, and private support has been essential in moving Davey’s research forward.

Early detection of Ebola virus disease is vital to treatment. Dr. Andrew Hayhurst, V&I Associate Scientist, has developed novel llama antibody libraries capable of targeting any chosen virus. Using this resource, his lab identified antibodies that recognized a small conserved region of a protein in Marburg virus with a very similar architecture to Ebola virus. This recognition could pave the way for early identification testing kits that can be used in the field.

Current testing methods for Ebola are only accurate in the later stages of the disease, usually well after an outbreak is in full swing. Developing a tool which is not dependent upon refrigeration and can identify Ebola virus early in infection can stop an outbreak in its tracks. A new National Institutes of Health R01 grant in 2015 will enable his team to further this research over the next five years.

Ebola virus dominated headlines and the minds of many of the world’s infectious disease scientists. Texas Biomed was already in a prime position to push this research forward. But Ebola isn’t the only lethal pathogen studied here. In addition to long-standing research on HIV, V&I scientists are conducting research on other hemorrhagic fever viruses including Lassa Fever Virus, Crimean-Congo Hemorrhagic Fever Virus, and other Filoviruses. They are also initiating studies on South American Arenaviruses and Alphaviruses.

While Ebola’s high fatality rate terrified the world, the most important lesson learned was that what happens in one part of the world has the potential to affect us all.

“We can take care of people who get sick here in the U.S., but we need to stop the outbreaks where they exist. Much of our work is focused on stopping the disease at the source,” Dr. Patterson said.
As one of only seven national primate research centers, the Southwest National Primate Research Center (SNPRC) is part of a nationwide consortium of institutions dedicated to advancing science through research with nonhuman primates. This research has led to a greater understanding of and treatments for diseases such as hepatitis, HIV, Ebola virus, diabetes, cardiovascular disease and so much more.

As people seek to understand how we can better treat or cure human diseases, more commonly referred to as translational medicine, nonhuman primate models are becoming increasingly more important.

In a recent paper authored by Texas Biomed Scientists Dr. Marcel M. Daadi, Dr. Tiziano Barberi, Dr. Qiang Shi, and Dr. Robert E. Lanford, published in Stem Cells and Development, Daadi states, “Humans and nonhuman primates (NHPs) are similar in size, behavior, physiology, biochemistry, structure and function of organs, and complexity of the immune system. Research on NHPs generates complementary data that bridge translational research from small animal models to humans.”

Texas Biomedical Research Institute launched a new regenerative medicine program in 2014 with the addition of Daadi and Barberi. Renowned in the field of stem cell science, these scientists both stated that key to their decision to join the Texas Biomed team was the unique resource provided by the primate center.

According to the International Society for Stem Cell Research, regenerative medicine focuses on “medical interventions that aim to repair damaged organs, most often by using stem cells to replace cells and tissues damaged by aging and by disease.”
Daadi and Barberi are working on a variety of interventions for such diseases as neurodegenerative disorders like Parkinson’s Disease, stroke and traumatic brain injury as well as muscular disorders like Muscular Dystrophy and diseases of the eye such as Macular Degeneration.

In order to ensure these stem cell therapies are safe and effective, researchers must first prove they work in a nonhuman primate model.

“The ultimate goal of safety and efficacy studies in nonhuman primate models is to better predict outcomes, address challenges and increase the likelihood of success in human clinical trials,” Daadi states in the Stem Cells and Development paper. “Research on nonhuman primates can generate complementary data that bridge translational research from small animal models to humans.”

Regenerative medicine is just one way in which nonhuman primate models are critical to combating human disease. Texas Biomed’s Department of Genetics looks at new ways to identify and discover gene targets and gene therapies for obesity, diabetes, atherosclerosis and other chronic diseases. Nonhuman primate models are as critical to this effort as they are to the testing of potential vaccines and cures for deadly pathogens, such as Ebola virus, hepatitis viruses and HIV.

Nonhuman primate models may also hold the key to identifying ways we can slow down the aging process and thus age-related diseases, like cardiovascular disease, Alzheimer’s, osteoporosis and much more.

Dr. Suzette Tardif joined the Southwest National Primate Research Center in 2014 as the Associate Director of Research. Tardif’s research has focused for more than 30 years on developing the common marmoset monkey as a biomedical model for disease.

Through a partnership with the Barshop Institute for Longevity and Aging Studies at the University of Texas Health Science Center at San Antonio, Tardif is working with collaborators to develop the marmoset as an efficient model in which to study aging. Studies have already shown positive results of one particular pharmaceutical intervention called Rapamycin. The drug was originally shown in 2009 to reliably increase lifespan in a rodent model; however, moving from rodents to humans requires greater study of the drug’s effectiveness, as well as its safety in a model more closely related to humans.

“We recently reported our ability to rapidly and reliably dose socially-housed marmosets with an oral form of Rapamycin that is well tolerated and results in suppression of the mTOR pathway,” Tardif said. “Specifically, we have to study the effect of aging interventions on the healthy lifespan of a primate.”

From stem cell therapy to gene therapy to pharmaceutical interventions for disease, the Southwest National Primate Research Center allows for the humane study of diseases and is a critical step in the process to advancing human health.

“We, as scientists and as citizens, understand that we must carefully consider our use of nonhuman primates in all research, but it is inherently clear that nonhuman primates were critical in helping us eliminate diseases of the past and will continue to be necessary to curing diseases of the future,” said Dr. Robert Lanford, Director of the Southwest National Primate Research Center. “We are passionate about being good stewards of such a critical resource and excited to be a vital link in the process of moving basic research from the lab to the bedside.”
The study of genetics is always evolving, nowhere more so than at Texas Biomed. Traditionally, geneticists have focused on finding the changes in genetic sequences that correlated with diseases or traits related to diseases. For example, work would focus on which gene variants are responsible for regulating glucose levels leading to diabetes or what genetic change affects a person’s risk for high cholesterol.

Dr. Michael Olivier, Chair of the Department of Genetics, explained how we currently understand and use genetics and where it is headed.

“Like a Lego kit, our DNA is made of building blocks. For example, to build a car, you need the building blocks and the manual. Thanks to all the statistical analyses we have historically done in genetics research, we now have a manual to our genetic code and can read it,” Olivier said. “But, what we don’t know is whether a Lego kit where not all the pieces perfectly match the manual or some might be missing will result in a different product at the end. How does a small genetic change make a difference in how we express that gene? And, does that change make a difference for developing specific diseases?”

The next step in genetics research is to answer that question, How? How does a specific mutation change the outcome at the molecular level? How does the cell respond to the genetic change?

The challenge is to investigate the molecular and cellular steps leading up to the final outcome, essentially testing whether putting that red Lego piece where a blue one was supposed to go makes the Lego car run differently.

Historically, Texas Biomed genetics research has focused on statistical analyses, which has provided a firm foundation for the study of genetic diseases. Now, scientists at Texas Biomed are in a unique position to understand the entire picture. They can combine the expertise of protein science, metabolic science, genetics and complex data integration and analysis with high throughput instrumentation, such as a mass spectrometer. This expertise is not typically available to a genetics group all under one roof.

Collaboration and cooperation is the key to continued success. One such area of collaboration includes the new regenerative medicine program at the Southwest National Primate Research Center at Texas Biomed.

Dr. Michael Olivier and Dr. Laura Cox
In the past, geneticists used transformed cells whose genetic makeup has been altered to study genetic changes. However, such cells have been altered substantially and therefore do not behave normally. As a result, it can be difficult to interpret the actual effect on cell function.

Induced Pluripotent Stem Cells (iPSCs) are cells that can differentiate into any type of cell and come from adult, rather than embryonic, tissue. Using iPSCs, scientists can induce a genetic mutation, and then study the cell as it progresses to its final stage, gaining insight into the molecular and cellular steps that lead to the different phenotype.

Using the Lego analogy, “This new technology means scientists can change one block of that Lego car, and see what happens,” Olivier said.

In the past, such studies would take months to simply develop the appropriate cell line before initiating the experiments. One significant advantage of iPSC technology is that the development process is condensed into a much shorter time frame. This will lead to more rapid identification of potential targets for new drugs for treatment and recommendations for prevention of a variety of genetic disorders.

The scientists at Texas Biomed are also taking advantage of Next Generation Sequencing (NGS), which overcomes previous issues of throughput, scalability, speed and resolution. The Department has been awarded a grant that will allow them to sequence 700 genomes of baboons from the pedigreed colony.

“This resource will be a game changer,” said Dr. Laura Cox, Scientist and Vice Chair of the Department of Genetics. “In the past, scientists relied upon large-scale population studies. Now they will be able to start with known genome sequences as the initial selection criteria when conducting studies.”

Work on early-stage human and nonhuman primate genetic research provides the foundation necessary for scientists to conduct translational research, the ultimate focus of researchers at Texas Biomed — taking science from the lab to the individual.
A collaboration that began in 2014 with the national organization Take Off Pounds Sensibly (TOPS) aims to look specifically at individual outcomes in a unique way. Texas Biomed has partnered with TOPS to begin work on a study that will identify individuals within families who, despite being exposed to the same lifestyle choices, do not gain weight, or individuals that have managed to lose weight and not gain it again. What makes these individuals different?

The study will focus on the interaction of food, behavior and genetics and try to answer questions about why one individual does not have the same reaction to food as another person.

Over the years, Texas Biomed scientists have gained a wealth of information about the genetics of obesity. By collaborating with local initiatives for health and wellness, such as Take Off Pounds Sensibly (TOPS), these organizations can make the most of the scientific expertise of Texas Biomed as an individual progresses on his or her journey to a healthier lifestyle.

Combining advanced technology in genetics research with programs using the outcome of that research in practical situations continues to place Texas Biomed scientists at the forefront of health and science.
MALARIA

Malaria continues to be an enormous problem throughout the world, with up to 500 million people infected annually and more than 2 million of those dying from the disease. The disease has a great impact on not only the health of a country but also on the education of its people and the economic health of that country. In our interconnected global village, a healthy economy affects us all.

The disease is caused by multiple parasites that have a long history of evolution with their hosts, with two species, Plasmodium (P.) falciparum and P. vivax, causing the most disease in humans. The parasites have proven to be canny, developing resistance to each of the five classes of drugs currently available.

To gain the advantage on these malaria parasites, scientists at Texas Biomed have been studying the mutations that lead to drug resistance. In the past, this required isolation of individual parasite clones from human infections, then analysis of their genetic differences. This labor-intensive task was slow and yielded very small quantities of DNA. Because infections are often mixed with multiple parasite clones, it is difficult to separate individual parasites. “It’s like trying to understand human genetics by taking DNA from everyone in a village at once. The data are all jumbled up — what we really want is information from individuals,” Dr. Ian Cheeseman, Staff Scientist in the Department of Genetics, said. Furthermore, since P. vivax cannot be grown in culture, all research was focused on P. falciparum.

Cheeseman and his team are making the most of new technology to tease out these genetic differences. By using fluorescent dyes, they can separate the parasite-infected red blood cells from the uninfected red blood cells by flow cytometry. This allows them to focus on only those cells that contain parasites with extremely small quantities of DNA. This method does not rely on growing the parasite in a cell culture, so studies can also be performed on P. vivax, a huge boost to research capabilities.

By identifying the mutations leading to drug resistance in both P. falciparum and P. vivax, the scientists have the potential to develop better treatment options and potential vaccine targets.
MATERNAL NUTRITION STUDY

Malnutrition is a significant problem worldwide, but also in the U.S., where more than 50 million Americans live in households with insufficient food. Scientists have long known that nutrient deficiency in pregnancy has a negative impact upon developing organs, but until now very little has been known about the impact on the developing brain. The long-held theory was that when deprived of sufficient calorie intake, the other organs would suffer to protect the primate brain.

New research by Texas Biomed’s Dr. Laura Cox, Scientist and Vice Chair in the Department of Genetics, and her colleagues at the University of Wyoming has indicated that the frontal cortex is also affected when the pregnant mother experiences nutrient deficiency. Because they can study this in nonhuman primates, Texas Biomed scientists have learned a great deal more about brain development than they could with the rodent models previously studied.

When pregnant baboons were fed a diet with 30 percent fewer calories than normal, they found very little effect in the brain stem. However, when they examined the frontal cortex, the center for higher order thinking and cognition, they found more significant changes. In the offspring, behavioral studies show greater impulsivity and decreased attention span in males, whereas in females, the effects were marginal.

The team then analyzed the placental tissue and found that female placentas had coordinated networks of development. That is, when deprived of nutrients, certain genes were up-regulated or down-regulated in a coordinated fashion which adjusted for the deficiencies. In the male placentas, however, they found that this coordination did not occur at the same level. When there were fewer nutrients, the male placentas did not adapt to the lower energy conditions and continued to try to develop all systems.

These differences, the first of their kind reported, suggest a reason why the survival rate of female offspring is greater than that of males. For a primate species to survive, more females are required than males. By adjusting for a less-than-ideal environment while in utero, the female offspring may be preparing for a suboptimal environment once born, and therefore has a survival advantage.

Cox and her team are taking these studies a step further by adjusting for specific amino acid deficiencies. Does adding one particular amino acid make a difference? In situations of nutrient deficiency, if one simple change has a significant impact, a supplement may be sufficient to improve maternal and neonatal outcomes.
HIV VACCINE STUDIES

As HIV infection continues to be a global health threat, there is still no cure and no vaccine. Texas Biomed scientists have taken a novel approach in developing an HIV vaccine. Dr. Ruth Ruprecht, Director of the Texas Biomed AIDS Research Program, says this particular vaccine focuses on stopping transmission of HIV at the mucosal barrier.

According to Ruprecht, 90 percent of all new HIV infections occur through mucosal exposure. However, there are individuals who, despite repeated exposure to HIV, do not become infected with the virus. This “natural immunity” is due to the presence of antibodies in their mucosal secretions, specifically IgA antibodies against the HIV gp120 envelope protein. A vaccine that could mimic this natural immunity and therefore prevent infection in other individuals would have a significant impact on transmission rates.

Until now, researchers traditionally have focused on creating a vaccine that elicits specific blood antibodies or cytotoxic T cells, but neither approach has been very successful to date. This new vaccine has been engineered to stop HIV from crossing the mucosal barrier, the initial point of infection. “The Myxometics HIV vaccine candidate uses building blocks from a special part of the HIV envelope protein, called gp120,” Ruprecht said.

Ruprecht’s team at Texas Biomed has built upon an earlier study in China that used a two-component vaccine protecting all monkeys tested against repeated HIV exposures. Ruprecht and her colleagues have taken this further by testing just one component of the vaccine at a time. They found that to be successful, an HIV vaccine must mount both a mucosal and systemic antibody response to the virus.

This strategy is called “defense-in-depth”—an approach to defend a vital core by pre-planned, well-armed, multiple lines of defense that can provide backup in case the frontline is breached. When HIV-1 encounters mucosal antibodies generated by the vaccine, those virions will be captured and blocked from crossing the mucosal barrier. However, some virions will remain free, penetrating the barrier. When they do, the second “host defense” will be the systemic antibodies generated as additional immune responses by the vaccine, which can then stop the remaining HIV-1 virions from spreading, preventing systemic infection.

These studies, funded by the Bill & Melinda Gates Foundation, are bringing Texas Biomed and the world one step closer to developing an effective vaccine against HIV infection.

Dr. Ruth Ruprecht
2014 Financials

2014 Revenue*

- 71% Grants & Contracts
- 12% Campaign Donations released from restriction
- 5.4% Endowment Income
- 3.8% Oil & Gas Royalties from Donated Properties
- 3.8% Unrestricted Donations
- 3.5% Donor-Funded Research
- 0.2% Other Income

* Based on 2014 Audited Financials

2014 Value of Endowment in Millions of Dollars

- 2010: $93.2
- 2011: $91.4
- 2012: $100.8
- 2013: $117.4
- 2014: $118.3
<table>
<thead>
<tr>
<th>National Institutes of Health</th>
<th>PRINCIPAL INVESTIGATOR</th>
<th>LENGTH</th>
<th>TOTAL AMOUNT TO TEXAS BIOMED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Southwestern National Primate Research Center</td>
<td>Dr. Robert Gracy</td>
<td>2 years</td>
<td>$ 14,899,244</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Matthew Johnson</td>
<td>5 years</td>
<td>$ 4,003,099</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Ricardo Carrión, Jr.</td>
<td>2 years</td>
<td>$ 3,215,169</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Anthony Griffiths</td>
<td>2 years</td>
<td>$ 3,215,169</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Jean L. Patterson</td>
<td>2 years</td>
<td>$ 3,215,169</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Michael Olivier</td>
<td>4 years</td>
<td>$ 2,693,124</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Ian H. Cheeseman</td>
<td>4 years</td>
<td>$ 2,287,500</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Laura A. Cox</td>
<td>4 years</td>
<td>$ 1,805,974</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Robert E. Lanford</td>
<td>1 year</td>
<td>$ 1,667,796</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Jean L. Patterson, Dr. Ricardo Carrión, Jr.</td>
<td>1 year</td>
<td>$ 1,045,323</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Robert Gracy</td>
<td>1 year</td>
<td>$ 694,579</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Laura A. Cox</td>
<td>5 years</td>
<td>$ 589,073</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Ruth M. Ruprecht</td>
<td>2 years</td>
<td>$ 551,985</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Laura A. Cox</td>
<td>3 years</td>
<td>$ 432,376</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Ricardo Carrión, Jr.</td>
<td>1 year</td>
<td>$ 260,767</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>Dr. Robert Daye</td>
<td>2 months</td>
<td>$ 163,494</td>
</tr>
</tbody>
</table>
### FEDERAL RESEARCH GRANTS AND CONTRACTS

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Length</th>
<th>Total Amount to Texas Biomed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>National Institutes of Health/Bavarian Nordic A/S</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development of Technologies that Accelerate the Immune Response to Bioterrorism Vaccines</td>
<td>Dr. Jean L. Patterson, Dr. Ricardo Carion, Jr.</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>National Institutes of Health/University of Texas Health Science Center San Antonio</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Novel Mouse Model of Obesity in Pregnancy</td>
<td>Dr. Laura A. Cox</td>
<td>6 months</td>
</tr>
<tr>
<td><strong>Total for Federal Research Grants and Contracts under $100,000</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$291,109</td>
</tr>
<tr>
<td><strong>TOTAL FEDERAL RESEARCH GRANTS AND CONTRACTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$34,772,739</td>
</tr>
</tbody>
</table>

### PHILANTHROPIC RESEARCH GRANTS

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Length</th>
<th>Total Amount to Texas Biomed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bill &amp; Melinda Gates Foundation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirming the Efficacy of Virologues Targeting HIV-1 gp41 in Indigenous Populations</td>
<td>Dr. Ruth M. Ruprecht</td>
<td>2 years</td>
</tr>
<tr>
<td><strong>Robert J. Kleberg Jr. &amp; Helen C. Kleberg Foundation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recruitment Package</td>
<td>Dr. Marcel Duand</td>
<td>3 years</td>
</tr>
<tr>
<td><strong>Robert J. Kleberg Jr. &amp; Helen C. Kleberg Foundation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recruitment Package</td>
<td>Dr. Tiziano Barletti</td>
<td>3 years</td>
</tr>
<tr>
<td><strong>William &amp; Ella Owens Medical Research Foundation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early Indicators of High Osteoarthritis Risk: The Road to Improved Patient Outcomes</td>
<td>Dr. Lorena M. Havill</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Total for Philanthropic Grants and Contracts under $100,000</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$1,384,161</td>
</tr>
<tr>
<td><strong>TOTAL PHILANTHROPIC RESEARCH GRANTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5,388,335</td>
</tr>
</tbody>
</table>

### COMMERCIAL RESEARCH GRANTS AND CONTRACTS

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Length</th>
<th>Total Amount to Texas Biomed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bavarian Nordic A/S</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunogenity and Protective Efficacy of MVA-EnF1 in an Ebola and a Marburg Challenge Model in Cynomolgus Monkeys, Supplement</td>
<td>Dr. Jean L. Patterson, Dr. Ricardo Carion, Jr.</td>
<td>3 months</td>
</tr>
<tr>
<td><strong>AMIGLU LLC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMIGLU Antibody Production</td>
<td>Dr. Robert Davey</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Novavax, Inc.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunogenity of Baculovirus Immunized Mice Challenged with Ebolavirus, Supplement</td>
<td>Dr. Ricardo Carion, Jr.</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Arrowhead Research Corporation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiviral Efficacy of RNAi in Chronic HBV Infection #3, Supplement</td>
<td>Dr. Robert E. Lanford</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Total for Commercial Grants and Contracts under $100,000</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$260,669</td>
</tr>
<tr>
<td><strong>TOTAL COMMERCIAL RESEARCH GRANTS AND CONTRACTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$1,100,698</td>
</tr>
</tbody>
</table>

### TOTAL MISCELLANEOUS RESEARCH GRANTS AND CONTRACTS

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOTAL GRANTS AND CONTRACTS AWARDED TO TEXAS BIOMED IN 2014</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$196,223</td>
</tr>
</tbody>
</table>

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$41,457,995</td>
</tr>
</tbody>
</table>
While the Texas Biomed team concentrates each day on realizing our mission to enhance lives through discovery, our donors and supporters remind us of why and for whom we strive for such breakthroughs. Donors from across the globe are investing in the ideas and innovations of our team. From the support of groundbreaking pilot studies to new equipment and laboratory space to the recruitment of individual scientists, our donors understand that the support they provide is critical to the future of human health, and for that, we are very grateful.

"WORDS FROM OUR CHAMPIONS…"

We have been supporters of Texas Biomed with our time, resources, and advocacy for more than 50 years dating back to the days of seeing Tom Slick’s vision grow into reality. We have enjoyed encouraging others to join us through our co-founding roles in the development of both the Forum and Founder’s Council. We are assured that our investments and love for the amazing research at Texas Biomed will live on to enhance the lives of us all into the future. — Jim and Tena Gorman

Giving to Texas Biomed has become a multi-generational affair in our family. We give to Texas Biomed because of their good work and the real-life impact this research has had locally and globally. — J.J. and Tracee Feik

As San Antonio natives, we have long known of the brilliant foundations originally envisioned and endowed by Tom Slick Jr. Our focus and fascination has been with one of his most prescient visions, Texas Biomed, for their leading edge research and efforts to understand and find answers to the mysteries of human health and well-being. Fortunately, we’ve had the added benefit to come to know and count each and every gifted researcher as an admired friend. Our family joins us — as do many of our friends — in following and supporting San Antonio’s great treasure, Texas Biomed. — Cappy and Suzy Lawton

To become a champion of scientific discovery, please contact Texas Biomed Vice President for Institutional Advancement and Public Relations, Corbett Christie at 210-258-9870 or cchristie@txbiomed.org, or visit our website at www.txbiomed.org and click on “Make a Difference.”
CIRCLES OF GIVING

Chairman’s Circle

Robert A. & Katheryn K. Anderson Foundation
Mr. and Mrs. Robert A. Anderson
AT&T Foundation
Dr. B. Paul Akin Jr.
Ruth and Edward Austin Foundation
Mr. and Mrs. Edward H. Austin Jr.
Mr. and Mrs. Richard N. Azar II
Mr. and Mrs. Sam P. Bell Jr.
Estate of Doris F. Rogers Bennett
Mr. and Mrs. Bruce Blakemore
Mr. and Mrs. Craig Boyan
Mr. and Mrs. Robert M. Cavender
Mr. and Mrs. Charles E. Cheever Jr.
Faye L. and William L. Cowden
Charitable Foundation
Broadway Bank Trustee
Ruth Chapman Cowles and
Andrew G. Cowles Memorial Trust
Ms. Phyllis Slick Cowell
Dr. Laura Cox and Jim Griffin
Dr. and Mrs. Thomas Luke Davis
Dickson-Allen Foundation
Douglass Foundation
Mr. Donald J. Douglas
Mr. and Mrs. Alan W. Dreeben
Edouard Foundation Inc.
Mr. and Mrs. Ron Finch
Mr. Donald G. Elliot
Ellwood Foundation
Mr. and Mrs. Walter Embrey Jr.
Mr. and Mrs. John W. Felt
Mr. H. Rugeley Ferguson
Fletcher Jones Foundation
The Founder’s Council
Mr. and Mrs. Larry Franklin
Frost
Gorman Foundation
Mr. and Mrs. James W. Gorman Jr.
Mrs. Helen Kleberg Groves
Mr. and Mrs. Jack Guenther
Jack and Valerie Guenther Foundation
Mr. and Mrs. Jack Guenther
Mr. and Mrs. Jack Guenther Jr.
Mr. and Mrs. George Kampmann
Mr. and Mrs. Jack E. Guenther Jr.
Gunn Family Foundation
Mr. and Mrs. Curtis C. Gunn Jr.
Mr. and Mrs. Frederic Hamilton
H-E-B
Mr. Charles C. Butt
Mr. and Mrs. Roger C. Hill Jr.
Mr. and Mrs. Tim Hixon
Mr. and Mrs. Tim Hixon
Holt Foundation
Mr. and Mrs. B.D. Holt
Mr. and Mrs. John R. Hubbard
Ms. Sara Smith Hubbard
Mr. and Mrs. William A. Johnson
The Henry J. Kaiser Family Foundation
Mr. and Mrs. George A. Kampmann Jr.
Mr. and Mrs. Richard Kardys
Mr. and Mrs. John C. Kerr
Robert J. Jr. and Helen C. Kleberg Foundation
Mr. Helen C. Alexander, Trustee
Mr. Henrietta K. Alexander, Trustee
Mr. John D. Alexander Jr., Trustee
Ms. Caroline A. Ferguson, Trustee
Mr. Helen K. Greens, Trustee
Ms. Emory Alexander Hamilton, Trustee
Mr. Dorothy A. Mott, Trustee
Klesse Foundation
Mr. and Mrs. William R. Klesse
Mr. and Mrs. Cappy Lawton
Mrs. Kim Lewis
Mr. and Mrs. Richard F. Lord
Mrs. Kathleen L. Luby
Ms. Mary Sue Marston
Mr. James R. Marvin III
Mrs. J. Richard Marvin
(in memoriam)
G. Harold and Leila Y. Mathers
Charitable Foundation
Mays Foundation
Mr. and Mrs. William A. Johnson
Mr. and Mrs. L. Lowry Mays
Mr. and Mrs. Mary F. Mays
McCombs Foundation
Mr. and Mrs. B. J. McCombs
The Honorable and Mrs. John Shields
Mr. and Mrs. John McLaughlin
V.H. McNutt Memorial Foundation
Mr. & Mrs. Jack Guenther
Mr. and Mrs. Marshall B. Miller and
Ms. Claudia Huntington
Mr. and Mrs. Lewis J. Moorman III
Ms. Patricia M. Muehr
Mr. Lathan Napier and
Dr. Dacia Napier
Mr. and Mrs. John E. Newman Jr.
Mr. and Mrs. Thomas M. O’Brien
William and Ella Owens
Medical Research Foundation
Phoenix Charitable Foundation
Mr. and Mrs. Rex Mitchell Amnini
Dr. and Mrs. James M. O. Rubin
Mr. and Dr. Richard T. Schoberg III
Sennies Foundation, Inc.
Mr. and Mrs. Thomas R. Sennies
Texas Biomedical Forum
Dr. and Mrs. Arnold B. Vardiman
Max & Minnie Tomerlin Voelcker
Foundation
Mr. David Beruth, Trustee
Mr. Bank M. Smith, Trustee
Mr. Forrest M. Smith III, Trustee
Mr. and Mrs. James C. Worth
Mr. and Mrs. Robert L. Worth Jr.
Mr. and Mrs. James P. Zachry

President’s Circle

Mr. and Mrs. Michael Richard Amnini
Mr. and Mrs. Brian Arriaga
Mr. and Mrs. John A. Asel
Mrs. Walter F. Brown
C.H. Guenther & Son Inc.
Mr. Dale W. Trotter
Mr. and Mrs. A.H. Cadwallader IV
Dr. and Mrs. Ronald K. Calgaard
Mr. and Mrs. Corbett Christie
Mr. and Mrs. Justin Colle
Ms. Carol A. Cox
Cox Smith Matthews Incorporated
Mr. and Mrs. James W. Smith Jr.

Continued
CIRCLES OF GIVING

Donors listed as of March 2015

Continued from pg. 23

Diamond Construction Company
Mr. and Mrs. Dean Oatman
Mrs. Marie Halff
Mr. and Mrs. Joe N. Haynes
Mr. and Mrs. John L. Hendry III
Herrmann Family Charitable Foundation
Mr. and Mrs. J. Scott Beckendorf
Mr. and Mrs. Mark J. Berridge
Mr. and Mrs. David S. Hermann
Mr. and Mrs. Ronald J. Hermann
Mr. and Mrs. Christopher Perry

Hixon Properties Inc.
Mr. Jack J. Spector
Mr. and Mrs. Anthony C. Johnson
Mr. and Mrs. Mark M. Johnson
Mr. and Mrs. Robert E. Kelso
Dr. and Mrs. Robert E. Lanford
Mr. and Mrs. Taylor Little
Mr. and Mrs. Clark R. Mandigo II
McGee Foundation
Mr. and Mrs. Edward C. Webb
Mr. and Mrs. Don B. McDonald
Ms. Lynn Tidwell Neff

Nordam Trust
Mrs. Robert R. Archer

Minnie Stevens Piper Foundation
Mr. and Mrs. Alex H. Oliver
Mr. and Mrs. Allan G. Paterson
Mr. and Mrs. Charles Urschel Slick

Stamburg Foundation
Mrs. Louis Stamburg

Rachel & Ben Vaughan Foundation
Mr. Ben F. Vaughan III
Mr. and Mrs. Richard Wade
Ms. Ann Brenandt Watson
Mr. and Mrs. Edward E. Whittacre Jr.
Whittacre Family Foundation
Mr. and Mrs. Edward E. Whittacre, Jr.
Mr. and Mrs. R. Clint Worth

Golden Circle
Mr. and Mrs. Ben Adams
The Honorable and Mrs. Clyde H. Alexander
Mr. and Mrs. Milton E. Allison Jr.

Argyle Foundation
Mr. and Mrs. Bob Marbut

Ms. Ann Griffith Ash
Mr. and Mrs. John B. Azar

Mr. and Mrs. Phil Bakke
Mr. and Mrs. Stephen P. Ballantyne
Mr. and Mrs. John Barnes IV
Mr. and Mrs. James Hunter Barrow
Ms. Erin M. Barry
Mr. Bruce B. Barshop
Mrs. Sam Barshop
Mr. and Mrs. Lee M. Bass
Mr. and Mrs. Christopher S. Batie
Mr. and Mrs. Jim Baxter
Mr. and Mrs. Brian Beem
Mr. and Mrs. Michael D. Beldon
Mrs. Marion Dewar Bell
Mr. and Mrs. Matthew M. Bell
Mr. and Mrs. Michael L. Benedum
Mr. and Mrs. Barry G. Benton
Mr. Jeffrey H. Berler
Mr. and Mrs. Mark J. Berridge

Eugenia & Lawrence A. Bertetti Foundation
Mrs. Lawrence Bertetti
Mr. and Mrs. Albert M. Biedenharn III
Mr. and Mrs. Lawrence T. Biedenharn
Ms. Margery L. Block
Mr. John Boldrick
Mr. and Mrs. Gary L. Bowers
Mr. and Mrs. Robert L. Bowers
Ms. Barbara Bowman
Ms. Lora A. Boyd
Brigadier General Julius H. Braun
Mr. David Bridges
Dr. Edward Briggs and
Dr. Sara McCannish
Brown Foundation Inc.
Mr. and Mrs. Thomas I. O'Connor III
Mr. J. Craig Browning Jr.
Mr. and Mrs. James C. Browning
Mr. and Mrs. Thomas O. Brundage
Mr. and Mrs. Harry H. Brusenhan
Mr. and Mrs. J. Bruce Bugg Jr.
Mr. and Mrs. Michael D. Burke
Mr. and Mrs. Guy Robert Boschman
Mr. and Mrs. Walter J. Buzzini III
Mr. and Mrs. Richard W. Calvert
Dean Charles E. Cantu
Mrs. Becky Butler Cap and
Dr. Andre P. Cap
Mrs. Cassandra C. Carr
Mr. and Mrs. Claiborne Ayres Carrington
Mr. and Mrs. William Carrington
Mr. and Mrs. Richard H. Cavender
Mr. and Mrs. James M. Cavender III
Ms. Jean Cheever
Mr. Robert R. Clemens
Mrs. Richard T. Coiner III
Mr. and Mrs. Norborne P. Cole Jr.
Concord Oil Company
Mrs. Tom E. Petzel
Mrs. George J. Condos
Mr. and Mrs. John B. Connally III
Mr. and Mrs. James H. Cowden
Mr. and Mrs. H. Markley Crosswell III
Ms. Rebecca A. Crowder
Mr. and Mrs. Joshua Cranston
Mr. and Mrs. Michael Cruz
Mr. and Mrs. James H. Cummings
Dr. Joanne Curran
Mr. and Mrs. Peter B. Dahlberg
Mr. and Mrs. James R. W. Daniell
Mrs. Bond Davis
Mr. Keith A. Davis
Ms. Helen Buchanan Davis
Mr. and Mrs. Leroy G. Denman Jr.
Mr. and Mrs. Robert Dewar
Mr. and Mrs. James F. Dicke II
Mr. and Mrs. William E. Dreyer
Dublin & Associates, Inc.
Mr. and Mrs. James R. Dublin
Mr. Thomas H. Edison
Mr. and Mrs. Ty Edwards
Mr. and Mrs. James D. Ellis
Mr. and Mrs. Michael Ellis
Mr. and Mrs. Richard W. Evans Jr.
Mr. and Mrs. Robert E. Fawcett Jr.
Mrs. Carolyn Grant Fay
Mr. and Mrs. John W. Frik Jr.
Kittie Nelson Ferguson Foundation
Mrs. Kittie West
Mr. Robert H. Finney and
Dr. Nancy A. Finney
Mr. and Mrs. Hugh Fitzsimmons Jr.
Mr. and Mrs. Edward C. Flato
Ms. Caroline A. Ferguson
Mr. Charles A. Forster
Mrs. Charles E. Foster
Ms. Staci Foster
Mr. and Mrs. Austra L. Franklin
Mrs. Jeannie Frazier and
Mr. David Frazier
Mr. and Mrs. Pat Frost
Mr. and Mrs. Bill Fugit
Mr. and Mrs. Carl Fuhrmann III
Mr. and Mrs. Mark Garcia
Mr. and Mrs. George A. Geis
Mr. and Mrs. James L. Glover
Dr. and Mrs. Joseph W. Goldzieher
Mr. and Mrs. Daniel Goodgame
Dr. and Mrs. William W. Gordon
Mr. and Mrs. John Paul Gould
Dr. and Mrs. Robert Gracy
Mr. and Mrs. Joseph Moorman Grant
Mr. and Mrs. William E. Greehey
Mr. and Mrs. Claiborne B. Gregory Jr.
Mr. and Mrs. Christopher J. Griffith
Mr. Cosmo F. Guido
Mr. and Mrs. Thomas L. Guido
Mr. and Mrs. Tracy Hammer
Mr. and Mrs. Houston Harte
Mr. and Mrs. James L. Hayne
Mrs. Frances J. Hearn
Mr. and Mrs. Jeffrey E. Heinke
Mr. and Mrs. Peter J. Hennessey III
Ms. Stacey Hill and
Mr. Erick Schlesher
Mr. Bryan Simpson Hixon
Mr. and Mrs. Timo Hixson
Dr. Peter W. Hollimon and
Dr. Mary H. Arno
Mr. and Mrs. Charles R. Hollimon
Mr. and Mrs. Charles M. Hornberger
Mr. and Mrs. Reagan Houston IV
Dr. Phillip S. H. and
Dr. Jane Lindell Hughes
Mr. and Mrs. John R. Hund Jr.
Mr. and Mrs. Kenneth M. Jastrow II
Mr. and Mrs. Greg Johnson
Mr. and Mrs. Ansley E. Johnston
Mrs. Joe Warren Jones
Julian Gold
Mr. and Mrs. Robert Gutierrez
Mr. and Mrs. and Mr. Paul S. Kane
Mr. and Mrs. William M. Kanyuk
Dr. and Mrs. Paul G. Kerby
Mrs. Sue Killam
Mr. and Mrs. Creston A. King III
Mr. and Mrs. Robert A. Kiolbassa
Mr. and Mrs. Richard M. Kleberg III
Mr. and Mrs. Bart C. Koontz
Mr. and Mrs. Edward K. Kopplow
Mr. and Mrs. John C. Korbell
Ms. Rosemary Kowalski
Mr. and Mrs. Michael L. Kreager
Mr. and Mrs. James Kruger
Dr. and Mrs. Ariel Kruger
Mr. and Mrs. William Jeffrey Kahn
Mr. and Mrs. Joseph B. Labatt
Mr. and Mrs. Bill N. Lacy
Lee Michaels Fine Jewelry
Mr. and Mrs. Ryan Berg
Lieutenant General and
Mrs. Frank E. Leidford Jr.
Mr. and Mrs. Steven Q. Lee
Mr. and Mrs. Byron L. LeFlore Jr.
Mr. Ralph Lohr Jr.
Mr. John R. Less
Mr. and Mrs. A. J. Lewis III
Mr. and Mrs. A. Jack Lewis Jr.
Maj. Gen. and Mrs. Homer L. Lewis
Mr. and Mrs. Mark Lewis
Mr. & Mrs. Steve C. Lewis
Mr. and Mrs. Walter Scott Light
Dr. and Mrs. David G. Lloyd
Mr. and Mrs. David G. Lloyd Jr.
Dr. and Mrs. Fernando Lopez
Mr. and Mrs. Porter Loring III
Mr. James A. Lube and Ms. Diane Hill
Mr. and Mrs. Gregory Mann
Mrs. Jamey Mannion
Ms. Ann Mannion
Martin Capital Advisors LLP
Mr. Paul Martin
Mrs. Gloria Gouger Massey
Mr. and Mrs. David Maazé
Dr. Paul and Dr. Christine Mayer
Mr. and Mrs. Jess Mayfield
Mr. and Mrs. Rob McClane
Ms. K. Heather McFarlin
McGaughey Construction Company
Mr. and Mrs. Ellen McGaughey
Dr. Henry C. McGill
Mr. and Mrs. Mark McLane
Mrs. Jo Lynne Meador
Mr. and Mrs. Richard Menchaca
Mr. and Mrs. Mitchell Meyer

Continued
CIRCLES OF GIVING
Donors listed as of March 2015

Continued from pg. 25

Mr. and Mrs. John A. Peveto Jr.
Mr. and Mrs. Philip J. Pfeiffer
Mr. and Mrs. Phillip M. Plant
Mr. Vincent Porter and
Dr. Cyndi Porter
Mr. and Mrs. Thomas L. Powell Jr.
Dr. Carl F. Raba Jr.
Mr. and Mrs. James L. Ramsey
Mr. and Mrs. R. Lane Riggs
Dr. and Mrs. Mark C. Rittenhouse
Mrs. Harold Roher
Mrs. Ruth Bowman Russell
Mr. and Mrs. Patrick R. Rutherford Jr.
Dr. and Mrs. Frank C. Summis III
Mr. and Dr. William and
Nancy Saunders
Mr. and Dr. Richard T. Schlosberg III
Mr. and Mrs. J. Thomas Schmidt
Roger & Priscilla Schultz
Family Foundation

Mr. and Mrs. Roger C. Schultz
Mrs. Helen J. Schupbach
Mr. and Mrs. Harry F. Schwethelm Jr.
Mr. and Mrs. Donnie Sey
Mr. and Mrs. Peter C. Selig
Dr. and Mrs. Antonio Serna IV
Dr. Robert E. Shade and
Mrs. Linda Freeman-Shade
Dr. and Mrs. R. Mark Sharp
Mr. and Mrs. Robert Eric Shaw
Ms. Kim Azar Shepperd
Mrs. Clara Showan
Mr. and Mrs. E. R. Sidwell
Silver Eagle Distributors
Mr. and Mrs. Bruce A. Smith
Mr. & Mrs. James B. Smith Jr.

Smith Protective Services

Mr. and Mrs. Pete LaRonde
Smothers Foundation

Mr. and Mrs. John E. Smothers
Mr. and Mrs. J. Dudley Snyder
Mr. and Mrs. Edward William Spalten
Ms. Doris Barshop Spector
Mrs. Marshall T. Steves Sr.
Mr. Julian C. Stewart

Mr. and Mrs. George L. Stieren
Mr. and Mrs. Leland M. Stone
Ms. Shelley M. Summers
Mr. and Mrs. Timothy L. Swan
Mr. and Mrs. Stephen Lee Swanson
Dr. and Mrs. Alvin Thaggard III
Mr. Richard Thompson
Mr. Kenneth P. Trevett
Mr. and Mrs. Arthur Uhl III
Mr. and Mrs. Jeffrey Vance
Dr. John L. Vandeberg
Dr. and Mrs. George J. Vassar
Mr. and Mrs. Curtis T. Vaughan III
Mr. and Mrs. Michael N. Venson
Mr. and Mrs. Jack Veder
Mr. and Mrs. W. Lawrence Walker Jr.
Mr. Neill Walsdorf Jr.
Mr. and Mrs. Thomas R. Ward
Mr. and Mrs. Mark E. Watson III
Mr. and Mrs. Don E. Weber
Mr. and Mrs. Dan G. Webster III
Mr. Alex P. Weekes
Mr. and Mrs. Ronald B. Weiss
Mr. and Mrs. C. Clark Welder
Mr. and Mrs. Jason Westmoreland
Mr. John H. White Jr.
Ms. Francine Whittenburg
Ms. Billinda Wilkinson
Mr. and Mrs. Jack Williams III
Mr. and Mrs. Thomas A. Wirth
Mr. and Mrs. Mark Woods
Mr. and Mrs. John H. White Jr.
Mr. Leon C. Wolfe Jr.
Mr. and Mrs. Todd Wallis
Dr. and Mrs. James W. Yancey
Mr. and Mrs. John M. Yantis
Mr. and Mrs. Peter Zacher
Mr. and Mrs. David S. Zachry
Mr. and Mrs. Joshua Zeller
Mr. and Mrs. Thad W. Ziegler

Mr. and Mrs. Scott Petty Jr.
Scott Petty Foundation

Mr. and Mrs. Scott Petty Jr.
The Texas Biomedical Forum is a non-profit group of more than 360 women from throughout San Antonio who serve as ambassadors for Texas Biomed in the community. Established in 1971, the Forum was developed specifically to support Texas Biomed through community relations, volunteer services and fundraising.

Each year, the Forum invites high school students from across the city to participate in tours of Texas Biomed. More than 200 students participated in these tours in 2014. Students learned about the many exciting discoveries happening at the Institute and the opportunities to further their own learning and a possible career in science.

The Forum also provides opportunities for its members and friends to learn directly from the scientists at Texas Biomed, as well as outside health experts, on issues relative to diseases being studied at the Institute. These activities started with a roundtable discussion in January followed by lecture luncheons in March and November of 2014 by Texas Biomed Scientist Dr. Ruth Ruprecht and Board Certified Pediatrician and Health Consultant Julie La Babua, M.D., FAAP.

During the spring lecture luncheon, the Forum also celebrated its 20th Annual Science and Education Awards organized by Jody Lutz and Sara McCamish in conjunction with the generosity and dedication of Valerie Guenther and the V.H. McNutt Memorial Foundation. Cash awards totaling $20,000 were given to area high school teachers whose innovative project proposals showed a significant commitment to science education in our community. The L.D Ormsby Foundation also supports the science awards by funding a stipend to all applicants.

The Forum’s annual gala is a premiere event in San Antonio and is the foundation of the group’s fundraising efforts each year. In March 2014, the Forum hosted its Spring Fashion Show at Neiman Marcus in advance of the gala festivities. Guests enjoyed a runway show featuring evening gowns for spring with all proceeds benefitting the Forum’s fundraising efforts.

The 2014 “La Dolce Vita” Gala was held May 3rd chaired by Daniella Serna and co-chaired by Ashley Hixon. Nearly 600 guests enjoyed on another sold-out evening of festivities raising $300,000.

These funds are provided to Texas Biomed scientists as “seed” monies to initiate new pilot projects that could eventually turn into larger-scale research studies with greater funding. A list of this year’s recipients and their research can be found on page 28 of this report.
In October 2014, the Forum kicked off its new year of activities with another great fashion show, “The Best of Fall” fashion show and luncheon at Julian Gold. A portion of the proceeds from that event benefited the 2015 Gala.

The Forum closed out its 2014 activities with a November luncheon honoring past Presidents of the Forum at the home of Karen Lee Zachry. It is through the vision of our founding President and members and the continued enthusiasm and dedication of our current membership and leadership that we are able to provide Texas Biomed with passionate volunteers and critical funds necessary to support research that saves lives.

Sincerely,

Melissa Morgan
2014 Forum President
The Founder’s Council is a dynamic group of individuals between the ages of 25 and 46 with the goal of building awareness among our city’s young talent and creating long-term philanthropic supporters for Texas Biomed.

The Founder’s Council was established in 1988 and now boasts more than 330 members from across San Antonio. Members’ annual donations help fund competitive grants to Texas Biomed scientists, and their outreach in the community is of great value as we seek to encourage more young professionals to become advocates for scientific research.

In 2014, the Founder’s Council was able to give Texas Biomed nearly $73,000 to fund competitive grants to researchers for the purchase of key pieces of scientific equipment, as well as unrestricted gifts from our higher-level members.

The Founder’s Council kicked off the year in February 2014 with a lecture luncheon featuring Scientist Dr. Ruth Ruprecht discussing whether antibodies against the AIDS virus are “Good Guys or Bad Guys.” Lecture luncheons are an opportunity for members and their friends to learn more about Texas Biomed’s research and scientists. A second lecture luncheon was held in September featuring the Department of Genetics Chair and Scientist Dr. Michael Olivier. His topic was “Can You Hear Me Now? Exciting New Discoveries on Hearing Loss.”

In March 2014, members enjoyed the premiere event, Dining and Discourse, where scientists from across all areas of research joined a table of 10 to discuss their science with an intimate group of members.

Throughout the year, we held several networking events for members and prospective members, and our major donors who support the Founder’s Council at a level of $500 and above enjoyed an “Epicurean Experience” at The Argyle. Members enjoyed socializing while having each course of a seated dinner paired with a wine.

At the Tobin Estate holiday party, we were honored to present the scientists with their equipment grant awards for the year.

The Founder’s Council exists to allow members the opportunity to meet and learn from the scientists, share what they’ve learned in the community and then support these scientific discoveries financially. The activities and fundraising support enables our members to play a vital role in helping Texas Biomed make a global impact, and we are proud to carry on this great tradition.

Sincerely yours,

Charley Hollimon
2014 President, Founder’s Council
Ms. Mallory Ahl
Mr. David M. Algelei
Mr. and Mrs. David Alvarez
Mr. and Mrs. Brett Alheim
Mr. Jonathan Amato
Dr. and Mrs. Garrett K. Andersen
Dr. Suhail Arasu*
Mr. and Mrs. Brian Arriaga*
Mr. Aaron Axel
Mr. and Mrs. John C. Axel
Ms. Tammy Ashby
Mr. & Mrs. Ben Azar
Mr. and Mrs. Jeff P. Bailey*
Mr. and Mrs. Brian Ballantyne*
Mr. Bryan Barton
Mr. and Mrs. Colton H. Batchelor
Ms. Josie Behrend
Mr. and Mrs. Brad Beldon
Mr. and Mrs. Matthew M. Bell*
Mr. and Mrs. Eduardo Berdegue
Mr. and Mrs. Ryan Berg*
Mr. Ray Bissmeyer
Mr. Sean M. Blasko
Mr. Chris A. Blasko
Mr. and Mrs. Jordan Booth
Ms. Lora A. Boyd*
Mr. Richard Boyer
Mr. and Mrs. Scott Boynton
Dr. Edward Briggs and
Dr. Sara McCannish*
Mr. and Mrs. Wesley Bright
Mr. Jeffrey Brouillard
Mr. J. Craig Browning Jr.*
Dr. and Mrs. John Browning
Mr. and Mrs. John Brooks
Mr. and Mrs. Jorge E. Canepo
Mr. Andrew Carthew
Ms. Rosa Vera and Mr. Joseph Carey*
Mr. & Mrs. Claborn Carrington
Mr. Paul B. Carter
Mr. W. B. Cavender
Mr. Lee Cavender
Mr. and Mrs. Corbett Christie*
Ms. Lauren Cininello
Mr. and Mrs. Brandon Clementson
Mr. and Mrs. Justin Cole*
Ms. Kelly A. Colotta
Mr. Kevin Covey
Mr. and Mrs. Kevin Cox
Mr. Andrew R. Craig
Mr. and Mrs. Carl Crane Jr.
Ms. Victoria Crowder
Mr. and Mrs. Joshua Crompton*
Mr. & Mrs. Michael Cruz
Dr. Joanne Curran*
Mr. and Mrs. Michael Darchicourt
Mr. and Mrs. Ryan David
Mr. Taylor Dawson
Mr. Trey Dawson
Mr. and Mrs. Jeffrey de Rojas
Dr. John and Dr. Annie DeKoch
Mr. Michael Dewar
Ms. Stephanie Dick
Mr. and Mrs. Kenneth Dorbandt*
Mr. and Mrs. Eric A. Dupre
Mr. and Mrs. Ty Edwards*
Dr. John D. Edwards
Mr. Robert C. Elbers and
Dr. Silvia Santinelli
Mr. and Mrs. John W. Feik Jr.*
Mr. & Mrs. Ron Finch
Mr. Robert H. Finney and
Dr. Nancy A. Finney*
Mr. Scott Foley
Ms. Staci Foster*
Mr. Robert Foster and Ms. Mary Rowe
Ms. Kay Freed
Mr. and Mrs. Andrew T. Friedman
Mr. and Mrs. Casey Fry
Mr. & Mrs. Triple Fuhrmann
Mr. & Mrs. Mark Garcia
Mr. & Mrs. David Gaskill
Mr. Greg Garrison and
Ms. Catriona Morrison
Ms. Lauren Geraghty
Mr. and Mrs. Matthew Gish
Mr. and Mrs. James B. Gouger*
Mr. and Mrs. Jack E. Guenther Jr.*
Ms. Jenni Haff
Mr. and Mrs. Joseph Hargrave
Ms. Caroleeene Hardlee
Mr. and Mrs. Daniel Hargrove
Mr. and Mrs. Edward Hart
Mr. and Mrs. Shawn Hatter
Mr. and Mrs. Ryan Haug
Mr. Cullen D. Jones and
Dr. Lorena M. Havill*
Mr. and Mrs. Clay Hefey
Mr. & Mrs. Jeffrey E. Heinke
Mr. and Mrs. Christian Herff*
Mr. & Mrs. David Herrmann
Mr. Jonathan Hess*
Mr. and Mrs. Jeffrey F. Hetrick
Mr. and Mrs. David Hildebrand
Ms. Carole L. Hill
Mr. and Mrs. Roger C. Hill III
Mr. Bryan Simpson Hixon*
Mr. and Mrs. Tim Hixon*
Mr. and Mrs. Charles R. Hollimon
Mr. and Mrs. John R. Hard Jr.*
Mr. and Mrs. Lawson Jesse
Mr. and Mrs. Anthony C. Johnson*
Dr. Joe Johnston
Mr. and Mrs. Chris Kardys
Mr. and Mrs. Tim Kelley
Dr. & Mrs. Paul Kerby
Ms. Millie Kerr
Mr. and Mrs. Claude K. Koontz
Mr. & Mrs. Will Kohmann
Ms. Stephanie Krueger
Mr. & Mrs. James Kruger
Ms. Camilla Labatt
Dr. Annie Montgomery Labatt
Mr. and Mrs. James F. Lane
Mr. and Mrs. Daniel Lasater
Mr. Trevor Lawson
Ms. Ann M. Leafstedt
Mr. and Mrs. Byron L. LeFlore Jr.*
Mr. and Mrs. Mark Lewis*
Mr. and Mrs. Stephen M. Little*
Mr. and Mrs. Taylor Little*
Mr. and Mrs. David G. Lloyd Jr.*
Ms. Katie Loflin
Mr. Manuel Long
Mr. and Mrs. Alcide M. Longoria
Mr. Jay Lucas
Ms. Natalie Bryan Marion
Ms. Lisa Martinez
Mr. Scott Matlock
Mr. and Mrs. David Mauze*  
Dr. Paul and Dr. Christine Mayer*  
Mr. Andrew McAllister  
Mr. & Mrs. Rob McClane  
Mr. & Mrs. Mark McLane  
Mr. and Mrs. Sean B. McNeelis*  
Mr. and Mrs. Robert McRae  
Mr. & Mrs. Mitchell Meyer  
Mr. and Mrs. Matthew Michelson  
Mr. and Mrs. Joe Miller*  
Mr. and Mrs. Michael L. Molak  
Mr. and Mrs. Ryan Moody  
Mr. and Mrs. John Moorman  
Mr. & Mrs. Lew Moorman  
Mr. and Mrs. Kelton Morgan*  
Mr. and Mrs. Mark W. Muecke  
Mr. Mel E. Myers  
Mr. Michael Nance  
Mr. and Mrs. Charles O'Brien  
Mr. and Mrs. Joseph P. O'Connor  
Mr. & Mrs. Steven Ogle  
Mr. and Mrs. Brian O'Gorman  
Dr. and Mrs. Michael Olivier  
Mr. and Mrs. H. Mills Palm Jr.  
Mr. and Mrs. Gardner Peavy*  
Mr. and Mrs. Daniel W. Peavy  
Mr. & Mrs. Christopher Petty  
Mr. and Mrs. Donald R. Philbin Jr.  
Mr. and Mrs. Phillip M. Plant Jr.  
Dr. & Mrs. Cameron Powell  
Mr. and Mrs. Andrew B. Price*  
Dr. and Mrs. Michael Profit  
Ms. Jenna Monette Reblin  
Mr. Krishna Reddy  
Mrs. Katie Reynolds  
Mr. & Mrs. J.B. Richter  
Mrs. Carla Martinez Riedl  
Mr. & Mrs. Lane Riggs  
Mrs. Cari Robinson  
Ms. Regina Rocha  
Mr. and Mrs. Robert Rochelle  
Mr. Don Rogers  
Mr. Wallace Rogers IV  
Mr. Paul A. Rolfs Jr.  
Dr. & Mrs. Jarro Rubin  
Mrs. Heather Welder Russo  
Mr. William and Dr. Nancy Saunders  
Ms. Amy Scott  
Ms. Nena M. Scott  
Mr. and Mrs. Forrest Seger  
Dr. and Mrs. Antonio Serna IV*  
Mr. and Mrs. Robert Shaw  
Mr. Ty Hunter Sheehan  
Ms. Kim Azar Shepperd*  
Dr. Gurpreet Singh  
Mr. Charles Slick Jr.  
Mr. and Mrs. William Spalten  
Mr. and Mrs. Alan Spalten  
Mr. John Robin Stewart  
Mr. & Mrs. Tripp Stuart  
Ms. Shelley M. Summers*  
Mr. And Mrs. Ben Swaney  
Mr. and Mrs. Frederick Thomson IV  
Mr. and Mrs. Jeffrey Vance*  
Mr. Nick Vanderpool  
Dr. and Mrs. George J. Vassar*  
Mr. and Mrs. Adam Vielock  
Mr. and Mrs. R. Bruce Walker  
Mr. and Mrs. Robert Watson Jr.  
Mr. & Mrs. Clark Welder  
Mr. and Mrs. Jason Westmoreland*  
Mr. Stephen J. Westmoreland  
Ms. Molly White  
Dr. Alexis Wiesenthal*  
Mr. & Mrs. Jack Williams III  
Mr. and Mrs. West Winter  
Mr. and Mrs. George J. Womack  
Mr. and Mrs. Elgin Wong  
Mr. Hunter Woolfolk  
Mr. Preston Woolfolk  
Mr. and Mrs. John H. Wright IV*  
Mr. & Mrs. Todd Wulfe  
Mr. & Mrs. Peter Zacher  
Mr. and Mrs. Joshua Zeller*  
Mr. and Mrs. Frank Zech  

* Adventurer/Explorer Members
For more than 50 years, The Argyle, a historic Southern mansion and unique private club, has been devoted to supporting the life-saving efforts of Texas Biomedical Research Institute. The more than 1,500 member club serves as a bond between one of the country’s leading independent research institutions and those who give time and money to support it.

Originally built in 1854 as the headquarters of a horse ranch, the mansion was an outpost of Texas hospitality. In 1954, Dr. Harold Vagtborg, the Institute’s first president, and Betty Slick Moorman, sister of founder Tom Slick Jr., discussed ways to interest more people in Texas Biomed’s work and to create a broader and more permanent base of support for its research programs. Betty Moorman suggested the establishment of a high-caliber club, the members of which would make an annual contribution to Texas Biomed, and thus The Argyle of today was formed.

Under the leadership of Michael Vlad, The Argyle underwent many changes in 2014. From personnel to facilities to member services, Vlad has transformed much of The Argyle’s offerings.

The Argyle underwent a redesign of the main alocve, the Hunt room, bar areas and several of the living quarters.

One of the biggest changes in 2014 was the hiring of Justin Keegan as the new Executive Chef. Keegan joined The Argyle from the St. Petersburg Yacht Club in Florida. He spent time in France working with internationally acclaimed chefs and spent six years at the Augusta Country Club in Georgia.

In an effort to provide even more to its members, The Argyle increased musical entertainment and purchased a new Japanese Kawai piano with the help of Mr. John Oberman. The Argyle also refurbished the 1929 Steinway piano thanks to the generosity of Mr. and Mrs. Jim Gorman.

Members were treated to “Special Nights at the Argyle” last year, featuring popular and unique fare. These were a nice addition to one of the most popular initiatives of The Argyle called “Fireside Chats.” This program allows members and their guests to meet with Texas Biomed scientists and others in a social setting to enjoy a conversational exchange of ideas, including the opportunity for questions and answers regarding the scientists’ research. The Argyle members enjoyed six of these chats in 2014.

Dr. Shelley Cole, Staff Scientist in Genetics, kicked off the 2014 talks in January discussing her work on The Strong Heart Study, a research project on the genetics of cardiovascular disease in Native Americans.

In February, Dr. Anthony Griffiths, Scientist in Virology and Immunology, talked about the work on vaccine development for filoviruses, such as Ebola virus disease.
John Kerr gave a special presentation about the history of The Argyle in April.

After a summer break, Chair of Texas Biomed’s Virology and Immunology Department Dr. Jean Patterson and Scientist Dr. Robert Davey discussed life in the BSL-4 laboratory, which allows Texas Biomed to research some of the world’s deadliest pathogens.

Dr. Mike Proffitt, Staff Scientist in Genetics, spoke on the future of genetics in October, and we closed out the year in November with a discussion on the promise of stem cell therapy in Parkinson’s Disease and other neurodegenerative disorders with one of Texas Biomed’s newest scientist Dr. Marcel Daadi.

The Fireside Chats continued to draw greater crowds and enthusiasm throughout the year and will continue into 2015.

Vlad said he looks forward to making additional renovations in 2015 to enhance the member experience, specifically remodeling the kitchen and elevator modernization.

“The benefits of a kitchen remodel will include food delivery time being reduced, increased menu versatility and high-volume production,” Vlad said. “Other improvements include the addition of a second access to the main dining room to increase the speed of service.”

He said his primary focus in the coming years will be to continue to improve member satisfaction.

“Our vision for an extraordinary club is providing the best quality and services while offering the best value,” Vlad added. “Our membership, staff and the vision that was created over 36 years ago has lasted the test of time. We have created a social club where members can entertain themselves, while financial contributions benefit medical research and give humanity hope and prosperity.”